Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Yervoy® (ipilimumab) – Expanded indication
February 15, 2023 - The FDA approved Bristol Myers Squibb’s Yervoy (ipilimumab), in combination with Opdivo® (nivolumab), for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older.
